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Introduction Cigarette smoking causes many chronic
diseases that are costly and result in frequent
hospitalisation. Hospital-initiated smoking cessation
interventions increase the likelihood that patients will
become smoke-free. We modelled the cost-effectiveness
of the Ottawa Model for Smoking Cessation (OMSC), an
intervention that includes in-hospital counselling,
pharmacotherapy and posthospital follow-up, compared
to usual care among smokers hospitalised with acute
myocardial infarction (AMI), unstable angina (UA), heart
failure (HF), and chronic obstructive pulmonary disease
(COPD).
Methods We completed a cost-effectiveness analysis
based on a decision-analytic model to assess smokers
hospitalised in Ontario, Canada for AMI, UA, HF, and
COPD, their risk of continuing to smoke and the effects
of quitting on re-hospitalisation and mortality over a
1-year period. We calculated short-term and long-term
cost-effectiveness ratios. Our primary outcome was
1-year cost per quality-adjusted life year (QALY) gained.
Results From the hospital payer’s perspective, delivery
of the OMSC can be considered cost effective with
1-year cost per QALY gained of $C1386, and lifetime
cost per QALY gained of $C68. In the first year, we
calculated that provision of the OMSC to 15 326
smokers would generate 4689 quitters, and would
prevent 116 rehospitalisations, 923 hospital days, and
119 deaths. Results were robust within numerous
sensitivity analyses.
Discussion The OMSC appears to be cost-effective
from the hospital payer perspective. Important
consideration is the relatively low intervention cost
compared to the reduction in costs related to
readmissions for illnesses associated with continued
smoking.
INTRODUCTION
Smoking-related illnesses are principal drivers of
healthcare spending; they are estimated to contrib-
ute up to 15% of healthcare expenditures in devel-
oped nations.1 Many of the chronic diseases caused
by cigarette smoking result in frequent hospitalisa-
tion making the hospital an ideal setting to initiate
cessation treatment.2 Rigotti and colleagues
recently updated a review and meta-analysis of
studies examining the efficacy of hospital-initiated
smoking cessation interventions. The interventions
included in the review were offered by hospital
staff (eg, physicians, nurses, or other allied health
professionals), and could involve the provision of
advice, intensive counselling, pharmacotherapy and
follow-up contact after hospital discharge. The
authors concluded that smoking cessation support
that began in hospital and continued for at least
1 month after discharge significantly increased the
likelihood of patients being smoke-free in the long
term (risk ratio=1.37, 95% CI 1.27 to 1.48; 25
trials), and that strategies that included counselling
and pharmacotherapy were more efficacious than
just counselling alone (relative risks (RR)=1.54,
95% CI 1.34 to 1.79, six trials).3
One of the studies included in the Rigotti review
was by researchers at the University of Ottawa
Heart Institute, of an intervention that is now
known as the Ottawa Model for Smoking
Cessation (OMSC).4 The OMSC is a systematic
approach to the identification, treatment and
follow-up of smokers that is embedded within hos-
pital management systems using organisational
change strategies. The OMSC has been found to
significantly increase long-term cessation rates by
an absolute 15% (from 29% to 44%) in cardiac
patients, and by 11% (from 18% to 29%) in
general hospital populations.4 5
Patients who quit smoking during hospitalisation
are less likely to be rehospitalised or to die during
follow-up.6 7 Despite such evidence, most hospitals
fail to deliver cessation interventions due, in part,
to concerns about the perceived costs of such pro-
grammes. Economic evaluations are becoming
increasingly popular in helping healthcare adminis-
trators choose whether or not to fund interven-
tions, and where to devote resources.8
Cost-effectiveness analysis (CEA) is a type of eco-
nomic evaluation that examines the consequences
or gains of an intervention compared to an alterna-
tive. The results of CEA are expressed as cost-
effectiveness ratios. For example, outcomes of CEA
for a smoking cessation programme might include
the cost per number of people who quit smoking,
cost per number of hospital-days prevented by the
programme, or cost per number of years of life
gained by the programme. Cost-utility analysis
(CUA) is a form of CEA that examines the cost of
an intervention relative to the benefit it produces in
terms of the number of years of life gained, com-
bined with the quality of those years lived. The
quality-adjusted life-year (QALY) is the most
common outcome measured in a CUA; it is a cost-
effectiveness ratio that takes into account quantity
and health-related quality of life.9
The purpose of this study was to determine, from
the hospital payer’s perspective, the short-term
(1 year) and long-term (lifetime) cost-effectiveness
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of the OMSC intervention, as compared to a usual care condi-
tion, among smokers hospitalised with acute myocardial infarc-
tion (AMI), unstable angina (UA), heart failure (HF), or chronic
obstructive pulmonary disease (COPD). This perspective and
these four diagnoses were selected for our analysis due to the par-
ticular burden of these tobacco-related diseases on hospitalisation
and rehospitalisation, and the availability of data.
METHODS
Setting
Our study examined patients hospitalised in Ontario, a Canadian
province with a population of approximately 12.8 million. The
smoking prevalence among Ontarians aged 15 years and older
was 15.4% in 2009.10 The smoking prevalence among Canadian
hospital populations is higher, at 20%11; consequently, on a
given day in Ontario, approximately 6400 of the province’s
32 000 hospital beds are occupied by current smokers.
Healthcare is publicly funded through the Ontario Health
Insurance Plan, where medically necessary services including
primary care and specialty care, hospital stays, diagnostic investi-
gations and surgical procedures are available at no cost to resi-
dents. There are 211 hospital sites in Ontario that recorded an
estimated 987 757 acute care inpatient admissions in 2009.12
Population
Our analysis included smokers hospitalised for one of the four
selected diagnoses. In 2009, there were 20 503, 5370, 16 339
and 17 585 unique admissions to Ontario hospitals for AMI,
UA, HF and COPD, respectively, for a total of 59 797, as
reported by the Canadian Institute for Health Information’s
(CIHI) Discharge Abstract Database (DAD).13 We combined
data from a previously published quasi-experimental, before
and after cohort study of the OMSC conducted at nine
Ontario hospitals,5 with data from similar evaluations that
took place at an additional 19 Ontario hospitals, in order to
estimate the number of these unique admissions that involved
smokers, and to estimate programme quit rates. Our study
dataset included patients (n=3269) aged 18 years or older who
were hospitalised for either AMI (n=750), UA (n=705), HF
(n=855), or COPD (n=956). Smokers were defined as anyone
who reported having smoked daily (≥1 cigarette per day) in
the 6 months leading up to their hospitalisation. The overall
smoking prevalence was 25.4%; disease-specific smoking rates
are displayed in table 1. Applying the disease-specific smoking
prevalence to the number of unique admissions, we estimated
that 15 326 smokers were hospitalised in 2009 for AMI
(n=5194), UA (n=1424), HF (n=2804), and COPD
(n=5904).
Table 1 Data elements included in the base case analysis ($ in $C)
AMI UA HF COPD Sources
Smoking prevalence rates (95% CI) 0.25 (0.22 to 0.29) 0.27 (0.23 to 0.30) 0.17 (0.14 to 0.21) 0.34 (0.29 to 0.38) 5
Age, mean (SD)
Usual care 56.9 (10.2) 58.0 (10.5) 60.8 (13.0) 62.3 (15.4) 5
OMSC 57.4 (13.1) 56.6 (12.9) 61.4 (10.4) 65.9 (10.6) 5
12-month smoking abstinence rates (95% CI)
Usual care 0.22 (0.15 to 0.30) 0.20 (0.13 to 0.30) 0.17 (0.10 to 0.27) 0.13 (0.08 to 0.21) 5
OMSC 0.38 (0.28 to 0.51) 0.35 (0.25 to 0.48) 0.28 (0.20 to 0.39) 0.24 (0.19 to 0.30)
Risk of one rehospitalisation in first year (95% CI)
Continue to smoke 0.05 (0.03 to 0.06) 0.10 (0.09 to 0.12) 0.17 (0.16 to 0.19) 0.18 (0.17 to 0.20) 7 17–20
Quit smoking 0.04 (0.03 to 0.05) 0.08 (0.07 to 0.10) 0.14 (0.13 to 0.16) 0.15 (0.14 to 0.16)
Risk of two or more rehospitalisations in first year (95% CI)
Continue to smoke 0.03 (0.02 to 0.04) 0.03 (0.02 to 0.05) 0.09 (0.07 to 0.11) 0.14 (0.12 to 0.15) 7 17–20
Quit smoking 0.02 (0.01 to 0.04) 0.03 (0.01 to 0.04) 0.08 (0.06 to 0.09) 0.11 (0.10 to 0.13)
Rehospitalisation cost, mean (SD) $9559 ($14 539) $5950 ($6932) $10 029 ($16 696) $8808 ($16 795) 21
Length of stay of rehospitalisation (days), mean (SD) 5.6 (9.8) 4.1 (4.9) 9.7 (12.8) 8.4 (14.5) 21
Risk of death in first year (95% CI)
Continue to smoke 0.14 (0.13 to 0.15) 0.09 (0.08 to 0.10) 0.48 (0.47 to 0.49) 0.09 (0.09 to 0.09) 19 20 22–25
Quit smoking 0.09 (0.08 to 0.10) 0.06 (0.05 to 0.07) 0.31 (0.30 to 0.31) 0.06 (0.06 to 0.06)
Utility scores
Continue to smoke 0.53 0.52 0.48 0.50 26 27
Quit smoking 0.55 0.54 0.50 0.52
Life expectancy, mean number of years remaining
Continue to smoke 7.58 7.42 5.19 7.75 28–30
Quit smoking 8.76 8.64 6.07 9.01
Intervention costs (per patient)
Personnel costs to complete in-hospital consultation $20.63 $20.63 $20.63 $20.63
In-hospital pharmacotherapy $13.95* $9.23* $21.60* $21.25*
Automated follow-up system fee $10.30 $10.30 $10.30 $10.30
Personnel costs to complete follow-up counselling calls $27.24 $27.24 $27.24 $27.24
Total intervention cost $71.50 $66.98 $78.81 $76.44
*Pharmacotherapy costs differ by diagnosis due to differing mean lengths of stay (LOS): AMI, mean LOS 5.6 days; UA, mean LOS 4.1 days; HF, mean LOS 9.7 days; COPD, mean LOS
8.4 days.
AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary diseases; HF, heart failure; OMSC, Ottawa model for smoking cessation; UA, unstable angina pectoris.
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Intervention
The OMSC was selected as the intervention in our model for
several reasons. It is the most widely implemented
hospital-initiated smoking cessation intervention in Canada. As
of 2014, it had been implemented in approximately 100 (14%)
Canadian hospitals. It features a large programme database
where data were available to generate some of our model’s data
elements, broken down by disease group. A Canadian interven-
tion was preferred as our estimates of cost and risk of rehospita-
lisation were derived from Canadian sources.
As part of the OMSC intervention, the following takes places
with each admitted smoker: (1) a 10–30 min consultation is
completed by a nurse or another healthcare professional (eg,
respiratory therapist) at the bedside, employing a standardised
consultation and assessment form. The form gathers informa-
tion on smoking history and readiness to quit. It guides the
health professional in the selection and ordering of quit
smoking medication, in giving practical advice, and registering
the patient in the follow-up support programme; (2) pharmaco-
therapy (primarily nicotine replacement therapy—NRT) is
offered to the patient for the duration of their hospital admis-
sion and ordered through the hospital pharmacy using standard
medication order forms; (3) guidance regarding the use of
smoking cessation pharmacotherapy following hospital dis-
charge is provided; (4) a patient education booklet with infor-
mation for those thinking about quitting, preparing to quit,
ready to quit, or wanting to stay smoke-free is provided; (5)
enrolment in a telephone follow-up system for 6 months after
discharge is offered. The telephone follow-up is conducted
using an automated system that places eight programmed calls
to smokers on days 3, 14, 30, 60, 90, 120, 150 and 180 after
their discharge date. Patients respond to automated questions
about their smoking status and their confidence in remaining
smoke-free. Their responses serve as a triage tool, and the
system flags those who have relapsed to smoking or who may
have low confidence in remaining smoke-free. Nurse counsellors
who specialise in smoking cessation treatment and relapse pre-
vention monitor the system and call patients who are flagged as
experiencing difficulty. The OMSC protocol and follow-up
system have been previously described in greater detail.4 5 14
Usual care
A number of guidelines exist recommending the integration of
tobacco cessation interventions within clinical practices in
Canada15 16; however, the large majority of hospitals in Canada
do not have in place smoking cessation protocols or pro-
grammes. Therefore, the most common alternative to our inter-
vention is usual care, which may consist of the recording of
smoking status on the patient chart and possibly the provision
of a patient education booklet.
Model framework
A decision analytic model was developed using an Excel spread-
sheet (Microsoft Corporation, USA). It included smokers hospi-
talised with AMI, UA, HF and COPD (15 326 in each the usual
care and OMSC branches), their RRs of continuing to smoke,
and the transitions to various states relating to health outcomes
among those who continued to smoke versus those who had
quit over the 1-year period (figure 1). The following 1-year
health states were included: no adverse outcomes, one rehospi-
talisation, two or more rehospitalisations, or death.
Data elements
The data elements used in our model’s base case analysis are
listed in table 1 and their sources identified.
Smoking abstinence rates
Smoking abstinence rates were obtained from our study dataset.
Self-reported 6-month continuous quit rates (ie, patient
responded ‘no’ when asked ‘have you used any form of tobacco
in the past 6 months?’) had been collected on a sample of
smokers who received either usual care (n=369) or OMSC
(n=439). They were calculated using intention-to-treat analysis
(ie, we assumed that those who were lost to follow-up were still
smoking) and were broken down by diagnosis. A 5% relapse
rate was applied to our 6-month quit rates in order to estimate
1-year quitting in our model based on a 2008 meta-analysis of
relapse by Hughes et al.31 Overall, the 12-month quit rate (95%
CI) was 17.9% (14.0% to 21.8%) for usual care and 28.5%
(24.3% to 32.7%) for the OMSC intervention. Disease-specific
rates are presented in table 1.
Rehospitalisation
We obtained values for the risk of being readmitted to hospital
one or two or more times in the year following the index hospi-
talisation for each diagnosis using data provided by CIHI. These
values were assigned to patients who had quit smoking. For con-
tinued smokers, the risk values were multiplied by the following
RR of being rehospitalised: 1.21 for AMI or UA7; 1.20 for
Figure 1 Decision analytic model. The square represents a decision
node. In this case we are evaluating the difference between
hospitalised smokers with AMI, UA, HF, or COPD receiving either usual
care or the OMSC programme. Circles A and B are chance nodes and
indicate where probabilities of two or more events occur (the events
are identical for each group but are only displayed for usual care). The
triangles indicate terminal nodes and are the end points we wish to
evaluate. AMI, acute myocardial infarction; COPD, chronic obstructive
pulmonary diseases; HF, heart failure; OMSC, Ottawa model for
smoking cessation; UA, unstable angina pectoris.
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HF20; and, 1.25 for COPD.19 To calculate a total number of
rehospitalisations, we multiplied the number of patients in each
group by the RRs and by a factor of 1 for one rehospitalisation,
and a factor of 2.5 for two or more rehospitalisations. The total
cost of rehospitalisations was obtained by multiplying the
number of rehospitalisations by the mean diagnosis-specific hos-
pital admission costs in 2009, as per the Ontario Case Costing
Initiative (OCCI).21 We calculated the number of hospital-days
used in the 1-year period following index hospitalisation for
recent quitters and continued smokers by multiplying the total
number of rehospitalisations in each group by the mean length
of stay for each diagnosis, obtained from OCCI.
Deaths
We obtained disease-specific mortality rates using published
studies of Ontario or Canadian patients.23–25 These rates were
assigned to patients who had quit smoking. For continued
smokers, the mortality rates were multiplied by the following
RR values for death: 1.50 for AMI or UA22; 1.41 for HF20;
and, 1.71 for COPD.19
Utility scores and life expectancies
Utility scores are estimates of health-related quality of life, and
are used to calculate the outcome of QALY. Utility values can be
between 1 and 0, with a score of 1 indicating perfect health and
0 representing death. The following utility values used were
obtained from a catalogue of scores for chronic conditions in the
USA: AMI (0.70), UA (0.69), HF (0.64), and COPD (0.66).26
These chronic-condition utilities were then multiplied by utility
scores of 0.75 for continued smokers and 0.78 for recent quit-
ters.27 Life expectancies for continued smokers and quitters were
obtained from published studies,28–30 and were discounted by
5% in the base case, as recommended by Canadian guidelines for
the economic evaluation of health technologies.32
Usual care costs
The estimated staff time involved with recording smoking status
and providing a patient education booklet is 1 min at a cost of
$C0.69 per smoker. Currently in Canada, the most widely used
patient education booklets are provided through the Canadian
Cancer Society (http://www.cancer.ca) and are available at no
charge to hospitals. The personnel costs for usual care and inter-
vention were based on the average 2009 hourly rate of a mid-
level registered nurse of $C33.2833 plus 24% extended bene-
fits34 for a total of $C41.27.
Intervention costs
Intervention costs did not include costs related to implementing
the programme, but included costs incurred by the hospitals for
operating the programme. These costs were based on previous
evaluations of the OMSC, and included: (1) personnel costs
associated with providing 30 min of bedside intervention
($C20.63 per patient); (2) the average daily cost of NRT
($C2.15 per patient, as determined by the University of Ottawa
Heart Institute Department of Pharmacy) multiplied by the rela-
tive length of stay for each diagnosis (determined by OCCI); (3)
telephone follow-up system and programme database manage-
ment fees ($C10.30 per patient; TelASK Technologies, Ottawa,
Ontario, Canada); and, (4) personnel costs associated with
40 min of monitoring of the follow-up system ($C27.24 per
patient).
Base case outcomes
Our base case analysis produced the following intermediate out-
comes for usual care and OMSC groups: number of quitters,
number of rehospitalisations, number of hospital-days, number
of deaths, number of life-years, and number of QALYs. The net
cost (total rehospitalisation costs saved minus total intervention
costs) and intermediate outcomes were used to calculate the
cost-effectiveness ratios. Our primary short-term outcome was
1-year cost per QALY gained. Additional 1-year outcomes were:
cost per quitter, cost per hospital-day avoided, and cost per
death avoided.
Long-term (ie, over the patient’s lifetime) outcomes included
lifetime cost per QALY gained and cost per life-year gained
(LYG). Mean age and life expectancies were used to calculate
total life-years for usual care and OMSC groups. Mean age by
diagnosis was obtained from the OMSC database. For long-term
QALYs, we multiplied the average life expectancy in each group
by the corresponding utility scores.
Sensitivity analyses
Univariate sensitivity analysis
We conducted a series of interviews with hospital decision
makers (n=22) and provincial healthcare policy analysts (n=5)
to determine what additional intervention components to con-
sider in our sensitivity analysis. The most common component
of interest was the addition of 12 weeks of cost-free NRT for
patients once they are discharged from hospital. Based on recent
reviews evaluating the efficacy of population-based and hospital-
based interventions that include NRT, we estimated that the
addition of 12 weeks of NRT would increase our programme
effectiveness by a relative 58%.3 35
For long-term outcomes, costs and benefits were discounted
at 5% in the base case. We used rates of 0% and 3% in the sen-
sitivity analysis as recommended by Canadian guidelines for the
economic evaluation of health technologies.32
Probabilistic sensitivity analysis
We performed a probabilistic sensitivity analysis to generate
uncertainty in the model using Monte Carlo simulation tech-
nique for our primary short-term outcome of 1-year cost per
QALY gained as well as for lifetime cost per QALY gained. This
is a common method used when economic evaluations are
based on patient-level or observational data to handle the fact
that data elements or ‘input parameters’ that go into the model
are imprecisely estimated from sampled data. In our case, this
applies to our input parameters of costs, quit rates, rehospitalisa-
tion rates, length of stay values and death rates. Each of these
Table 2 Projected cost outcomes of OMSC intervention compared








Intervention costs $10 575 $1 139 070 $1 128 495
Repeat hospitalisation costs in year following index hospitalisation
AMI $5 984 453 $5 808 343 ($176 110)
UA $1 474 391 $1 433 128 ($41 263)
HF $10 991 834 $10 777 828 ($214 007)
COPD $26 901 393 $26 289 058 ($612 335)
Total $45 362 645 $45 447 426 $84 781
Per patient $2960 $2965 $5
AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary diseases;
HF, heart failure; OMSC, Ottawa model for smoking cessation; UA, unstable angina
pectoris.
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parameters included a SD or 95% CI which were the distribu-
tions used to handle the uncertainty in our model. The uncer-
tainty of all the parameters was assessed simultaneously and was
characterised as b distributions (probability between 0 and 1).
Our model was evaluated 5000 times, with each simulation
involving a random draw from each of the input parameter dis-
tributions. In our study, 5000 estimates of costs and QALYs
were obtained and were presented by two cost-effectiveness
acceptability curves (CEAC)—one for short-term and one for
long-term QALYs. The CEACs report the probability that the
intervention is cost effective compared to usual care for alterna-




Table 2 presents the cost outcomes of the OMSC intervention
compared to usual care by diagnosis. From the hospital payer
perspective, providing the OMSC programme to 15 326
smokers with AMI, UA, HF, or COPD would cost an average of
$74 per smoker, or $1 139 070 per year. This investment would
generate 4689 new quitters and would prevent 116 repeat hos-
pitalisations, 923 hospital days, and 119 deaths in the first year.
The base case intermediate outcomes are presented in table 3.
Overall, the intervention resulted in the following 1-year cost-
effectiveness ratios: cost per QALY gained of $C1386, cost per
quitter of $C20, cost per hospital day avoided of $C103, and
cost per death avoided of $C803. The disease-specific and
overall cost-effectiveness ratios are summarised in table 4.
Long term
The OMSC intervention resulted in an overall lifetime cost per
QALY gained of $C61 and cost per LYG of $C36. The OMSC
was dominant (ie, overall costs are lower and QALYs and life-
years are higher) over usual care in patients with COPD and
resulted in greater lifetime QALY and life-years for each of the
diagnoses. The lifetime QALY gained were 0.31 per smoker
with AMI, 0.29 per smoker with UA, 0.15 per smoker with HF,
and 0.20 per smoker with COPD. The overall number of life-
years gained per smoker was 0.40.
Sensitivity analyses
The univariate sensitivity analysis results are presented in
table 4. In the base case analysis, quit smoking medications were
only provided to the patients during their hospital admission.
The provision of 12 weeks of NRT to patients following their
hospitalisation increased the per-patient intervention cost by
$C346, and produced an overall 1-year cost per QALY gained
of $C24 606, and lifetime cost per QALY gained of $C1071
For the long-term cost-effectiveness ratios, the programme
remained cost effective when 0% and 3% discounting was applied.
Figure 2 presents the CEAC for 1-year QALY by diagnosis.
The probability that the OMSC is most cost effective compared
to usual care was greater than 90% for AMI and HF and over
70% for UA and COPD for all values of 1-year QALY from $C0
to $C100 000 (figure 2).
In the case of lifetime QALY, the CEACs in figure 3 demon-
strate that the probability that the OMSC is the most cost-
effective alternative was greater than 90% for all diagnoses.
DISCUSSION
Not surprisingly, our results indicate the economic burden to the
hospital system of continued smoking is large. Hospitalisation is
an opportune time to initiate smoking cessation treatment as
smokers are frequent and high cost users of the healthcare system
and are often highly motivated to quit smoking during their
admission. Smokers would benefit significantly from receiving ces-
sation support while in hospital in terms of being able to quit
smoking and reducing their risk of morbidity and mortality. An
estimated $C547 million is spent each year in Ontario on hospita-
lisations for AMI, UA, HF and COPD alone. Our study estimates
that provision of the OMSC intervention to smokers admitted
with these issues would represent 0.20% of this cost, yet could
result in several individual and health system benefits and, in the
case of COPD patients, could result in actual cost savings.
However, there is an apparent expectation of behavioural or
preventative interventions, including smoking cessation, to dem-
onstrate that they are cost saving or able to save lives with little
Table 3 Base case outcomes of OMSC compared to usual care in












12 657 10 637 2020





Total 5024 4908 116
1 year hospital days, n
AMI 3506 3403
UA 1016 988
HF 10 631 10 424
COPD 25 655 25 071
Total 40 808 39 886 923





Total 2550 2431 119
Life years, n
AMI 40 703 41 701
UA 9975 10 282
HF 8616 9015
COPD 42 497 43 479
Total 101 791 104 476 (2685)





Total 7175 7244 (69)
QALYs (lifetime), n
AMI 21 701 22 383
UA 5741 5920
HF 7189 7353
COPD 23 386 23 911
Total 58 017 59 568 (1551)
AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary diseases; HF,
heart failure; OMSC, Ottawa model for smoking cessation; QALY, quality adjusted life
year; UA, unstable angina pectoris.
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investment. By contrast, this requirement does not exist to
nearly the same extent when it comes to other medical or pro-
cedural interventions for chronic diseases, for instance, treat-
ments for hyperlipidaemia or vascular surgeries. Given the
known benefits of smoking cessation on morbidity and mortal-
ity, it is our opinion that cessation interventions should be
adopted regardless of their ability to save money. If smoking ces-
sation interventions are indeed cost saving, this should be seen
simply as a favourable consequence of helping people to quit.
Results as compared to other studies
An earlier investigation revealed that a nurse-led smoking cessa-
tion intervention for patients hospitalised for AMI cost $C220
per LYG in 1991 US dollars (approximately $C628 per LYG in
current Canadian dollars).36 In that study, the intervention was
estimated to reduce smoking by 26%, more than twice as much
as our estimate. We believe our estimate of the effect of the
OMSC intervention on quitting is a more accurate reflection of
what can be achieved in 2012. More recently, Ladapo et al6 pro-
jected the cost-effectiveness of smoking cessation interventions
for a hypothetical US cohort of 327 600 smokers hospitalised
with AMI employing in-hospital counselling and follow-up tele-
phone calls from a nurse after discharge, but did not include the
use of pharmacotherapy in the base case; their programme
would cost $C540 per quitter and $C4350 per LYG.
Comparatively, the OMSC cost-effectiveness ratios for smokers
with AMI of $C99 per quitter and $C196 per LYG can be con-
sidered highly appealing.
Our long-term cost-effectiveness ratios are also highly attract-
ive when compared to several other interventions routinely used
to treat patients with smoking-related conditions (or their seque-
lae), including: b-blocker use after AMI (≈$C10 000 per LYG)37;
inhaled corticosteroids for treatment of COPD (≈$C30 000 per
Figure 2 Cost effectiveness acceptability curves by disease showing
change in the probability that the OMSC is cost-effective as the value
of QALY (1-year) changes. OMSC, Ottawa model for smoking cessation.
QALY, quality adjusted life year;
Table 4 Cost-effectiveness ratios of OMSC compared to usual care












1 year cost per QALY gained
AMI $6874 $25 496
UA $8482 $32 328
HF $472 $19 834
COPD Dominant $24 126













Cost per death avoided
AMI $4494 $16 668
UA $7790 $27 784
HF $169 $7544
COPD Dominant $17 435
Overall $803 $14 658
Long-term outcomes
Lifetime cost per QALY gained
AMI $286 $1062 $109 $207
UA $303 $1154 $118 $220
HF $42 $1564 $23 $34
COPD Dominant $885 Dominant Dominant
Overall $68 $1071 $24 $45
Cost per LYG
AMI $196 $726 $68 $137
UA $177 $674 $69 $128
HF $17 $723 $11 $15
COPD Dominant $474 Dominant Dominant
Overall $36 $629 $14 $26
AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary diseases; HF,
heart failure; LYG, life-year gained; OMSC, Ottawa model for smoking cessation;
QALY, quality adjusted life year; UA, unstable angina pectoris.
Figure 3 Cost effectiveness acceptability curves by disease showing
change in the probability that the OMSC is cost-effective as the value
of QALY (lifetime) changes. OMSC, Ottawa model for smoking
cessation. QALY, quality adjusted life year;
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LYG)38; cardiac resynchronisation therapy for HF (≈$C50 000
per LYG)39 ; hemodialysis for renal insufficiency (≈$C50 000 per
LYG)40; and, percutaneous coronary intervention for coronary
artery stenosis (>$C200 000 per LYG).41
Study limitations
Our study has several limitations. We did not model dynamic
changes in smoking status that can occur over time, nor did we
have data concerning effects of the OMSC on quit rates longer
than 12 months after hospitalisation. Only a small percentage of
smokers (3–5%), however, spontaneously quit smoking, and
smokers who are abstinent at 12 months have a 95% likelihood
of being smoke-free at 24-month follow-up.42
We did not account for smoking cessation interventions that
may have occurred outside of the hospital in either group. It is
possible that smokers may have received support that would
have generated additional costs; however, we did not model
these potential costs in our current study. Before applying our
results, readers need to consider that four distinct patient popu-
lations were examined in our model, and results may not be
transferable to other patient populations. We examined a mod-
erately intensive intervention provided in an acute care setting,
and application of our data to other interventions or healthcare
settings should be done with caution. Further, usual care or the
most common alternatives available in other countries may
differ from the usual care scenario in Canada that was applied
in our model.
Some of our data elements, for instance, our RR of rehospita-
lisation and death and our utility score estimates, were drawn
from older studies, and in the case of COPD risks, a longitu-
dinal observational trial.19 20 22 27 30 We included distributions
for all input parameters except utility scores and life expectan-
cies as they were unavailable in the studies we used; therefore,
we were unable to assess the uncertainty of these parameters in
our probabilistic sensitivity analysis.
It might be speculated that patients who quit smoking after
hospitalisation are sicker than those who continue to smoke.
Because our risk estimates were drawn from observational data,
they likely underestimate the harms of continued smoking. We
did not consider the effects of quitting smoking on preventing
other important smoking-attributable illnesses (eg, cancers,
stroke, peripheral vascular disease, other respiratory diseases,
and other cardiac diseases). We chose to examine costs and out-
comes specifically related to hospitalisations. There is a dearth
of information when it comes to the impact of smoking cessa-
tion on other important healthcare system costs and savings, for
instance, those related to emergency department, specialty-care
and primary-care visits. Future studies should examine a wider
array of healthcare impacts, and consider a societal perspective
that would also take into account productivity gains or losses.
Quitting smoking has been associated with gains in societal
productivity; it is thought that the inclusion of such information
would further improve an understanding of the cost-
effectiveness of the intervention.43 44 Our study only examined
costs and benefits that occurred in the first year. Evidence sug-
gests that patients who quit may be at reduced risk for hospital-
isation, morbidity and death in subsequent years, as the benefits
of cessation accrue over time.7 23 29 30
CONCLUSIONS
Due to population ageing and the costly burden of chronic dis-
eases that exists globally, hospitals and healthcare payers are
searching for cost-effective solutions, including primary and sec-
ondary prevention strategies. Implementation of the OMSC
hospital-initiated intervention for smoker-patients appears to be
a highly cost-effective option from the hospital payer’s perspec-
tive. Important consideration is the relatively low intervention
cost compared to the reduction in costs related to readmissions
for illnesses associated with continued smoking.
What this paper adds
▸ Most hospitals fail to offer tobacco cessation interventions
due, in part, to concerns about the perceived costs of such
programs. Cost-effectiveness analyses provide health care
administrators with information needed to guide the
allocation of resources.
▸ This study demonstrated that hospital-initiated smoking
cessation interventions, like the Ottawa Model for Smoking
Cessation, can be implemented with relatively small
investment and can be extremely cost-effective when applied
to high risk smokers with existing chronic disease.
▸ Given the known benefits of smoking cessation on morbidity
and mortality, cessation interventions should be adopted by
hospitals regardless of their ability to save money. If these
interventions result in cost-savings, this should be seen
simply as favourable consequence of helping people to quit.
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